Close

Exelixis (EXEL) Receives EC Approval of CABOMETYX as RCC Treatment Following VEGF-Targeted Therapy

Go back to Exelixis (EXEL) Receives EC Approval of CABOMETYX as RCC Treatment Following VEGF-Targeted Therapy

Leerink Positive on Exelixis (EXEL) as Cabometyx Nabs European Approval

September 14, 2016 8:50 AM EDT

Leerink affirms Exelixis (Nasdaq: EXEL) at Outperform with a price target of $12 after the company announced that the... More